The role of secondary surgery in recurrent ovarian cancer

D. Lorusso; M. Mancini; R. Di Rocco; R. Fontanelli; F. Raspagliesi

doi:10.1155/2012/613980

The role of secondary surgery in recurrent ovarian cancer

D. Lorusso, M. Mancini, R. Di Rocco, R. Fontanelli, F. Raspagliesi

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30 and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.

Original language	English
Article number	613980
Journal	International Journal of Surgical Oncology
Volume	2012
DOIs	https://doi.org/10.1155/2012/613980
Publication status	Published - 2012

ASJC Scopus subject areas

Oncology
Surgery

Access to Document

10.1155/2012/613980

Fingerprint Dive into the research topics of 'The role of secondary surgery in recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this

@article{0b8589c7f283490aaf9dc73d62f08370,

title = "The role of secondary surgery in recurrent ovarian cancer",

abstract = "Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30 and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.",

author = "D. Lorusso and M. Mancini and {Di Rocco}, R. and R. Fontanelli and F. Raspagliesi",

year = "2012",

doi = "10.1155/2012/613980",

language = "English",

volume = "2012",

journal = "International Journal of Surgical Oncology",

issn = "2090-1402",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The role of secondary surgery in recurrent ovarian cancer

AU - Lorusso, D.

AU - Mancini, M.

AU - Di Rocco, R.

AU - Fontanelli, R.

AU - Raspagliesi, F.

PY - 2012

Y1 - 2012

N2 - Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30 and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.

AB - Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30 and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.

UR - http://www.scopus.com/inward/record.url?scp=84866183391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866183391&partnerID=8YFLogxK

U2 - 10.1155/2012/613980

DO - 10.1155/2012/613980

M3 - Article

C2 - 22919475

AN - SCOPUS:84866183391

VL - 2012

JO - International Journal of Surgical Oncology

JF - International Journal of Surgical Oncology

SN - 2090-1402

M1 - 613980

ER -